www.fdanews.com/articles/196554-ely-lilly-offers-35-insulin-co-pay-in-response-to-covid-19
Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19
April 8, 2020
Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis.
The new co-pay card program covers most Lilly insulins, including all Humalog formulations, and all existing cards have been reset to a $35 co-pay.
The cards are not available for patients with government insurance, such as Medicaid and Medicare, or those getting state assistance.